We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Australia’s drug regulatory agency is urging drugmakers to reassess their quality control and data management systems after agency officials found frequent data integrity violations during GMP inspections over the past five years. Read More
GMP woes for foreign and domestic facilities continued as the FDA issued three warning letters to Indian and Chinese factories as well as a U.S. facility over data integrity and quality control problems. Read More
Divi’s Laboratories has been warned by the FDA for failing to meet current good manufacturing practice requirements, adding to the Indian drug manufacturer’s compliance woes. Read More